Autologous oocyte cryopreservation in women aged 40 and older using minimal stimulation IVF

Reproductive Biology and Endocrinology

Mingxue Yang¹  Simon Choo¹  John J. Zhang¹ 

[1] Reproductive Endocrinology and Infertility, New Hope Fertility Center, 4 Columbus Avenue, New York, NY, USA

关键词: Oocyte freezing;    Mild ovarian stimulation;    Minimal ovarian stimulation;    Oocyte cryopreservation;    IVF;   

Others  :  1231186
DOI  :  10.1186/s12958-015-0110-4

 received in 2015-08-27, accepted in 2015-09-30,  发布年份 2015

【 摘 要 】

Background

The value of oocyte cryopreservation in older women remains controversial. The aim of this study was to report the oocyte freezing experience in women aged 40 and older at a single fertility center.

Findings

One hundred fifty eight women (mean age 43.9 ± 0.2) who underwent minimal ovarian stimulation IVF were enrolled. IVF protocol included the use of clomiphene citrate (50 mg/day) or letrozole (2.5 mg/day) with or without low dose gonadotropins (started at 75 IU/day and increased as needed to 150 IU/day). 584 retrieved oocytes (2.1 ± 0.15 per patient) yielded 532 mature MII oocytes that were frozen. After thawing and fertilization by ICSI, a total of 344 embryos (1.9 ± 0.1 per patient) were formed. A total of 57 relatively good embryos were transferred and yielded three live births (5.3 % per embryo transfer), three spontaneous abortions, and one chemical pregnancy.

Conclusions

These data are important in counseling older women who desire autologous oocyte freezing.

【 授权许可】

   
2015 Zhang et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 2005;34:57–9.
• [2]Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013; 99:37-43.
• [3]Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006; 86:70-80.
• [4]Smith GD, Serafini PC, Fioravanti J, Yadid I, Coslovsky M, Hassun P et al.. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril. 2010; 94:2088-2095.
• [5]Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014; 101:1237-1243.
• [6]Fadini R, Brambillasca F, Renzini MM, Merola M, Comi R, De Ponti E et al.. Human oocyte cryopreservation: comparison between slow and ultrarapid methods. Reprod Biomed Online. 2009; 19:171-180.
• [7]Zarek SM, Muasher SJ. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. Fertil Steril. 2011; 95:2449-2455.
• [8]Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab. 2003; 88:166-173.
• [9]Zhang J, Merhi, Z., Yang, M., Bodri, D., Chavez-Badiola, A., Repping, et al. Minimal stimulation IVF versus conventional IVF: a randomized controlled trial. American journal of obstetrics and gynecology. 2015, In press.
• [10]Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online. 2005; 11:300-308.
• [11]Garcia-Velasco JA, Domingo J, Cobo A, Martinez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013; 99:1994-1999.
• [12]Cobo A, Garcia-Velasco JA, Domingo J, Remohi J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013; 99:1485-1495.
• [13]Zhang J, Chang L, Sone Y, Silber S. Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer. Reprod Biomed Online. 2010; 21:485-495.
• [14]Craig BM, Donovan KA, Fraenkel L, Watson V, Hawley S, Quinn GP. A generation of childless women: lessons from the United States. Womens Health Issues. 2014; 24:e21-27.
• [15]Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011; 95:747-750.
• [16]Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril. 1997; 67:110-114.
• [17]Seifer DB, Maclaughlin DT. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007; 88:539-546.
• [18]Merhi Z, Zapantis A, Berger DS, Jindal SK. Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve. J Assist Reprod Genet. 2013; 30:1361-1365.
• [19]Ubaldi F, Anniballo R, Romano S, Baroni E, Albricci L, Colamaria S et al.. Cumulative ongoing pregnancy rate achieved with oocyte vitrification and cleavage stage transfer without embryo selection in a standard infertility program. Hum Reprod. 2010; 25:1199-1205.
• [20]Borini A, Levi Setti PE, Anserini P, De Luca R, De Santis L, Porcu E et al.. Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome. Fertil Steril. 2010; 94:1662-1668.
• [21]Bianchi V, Lappi M, Bonu MA, Borini A. Oocyte slow freezing using a 0.2–0.3 M sucrose concentration protocol: is it really the time to trash the cryopreservation machine? Fertil Steril. 2012; 97:1101-1107.
• [22]Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G et al.. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012; 27:1606-1612.